Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saredutant plus paroxetine in major depressive disorder
2007-003863-31Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of saredutant and paroxetine in major depressive disorder (MDD) (3 arms), sponsored by Sanofi. Primary endpoint: Change from baseline in 17-item Hamilton Depression Rating Scale total score. Started Jan 2008; status: completed.
02
Drugs
saredutantparoxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2007-003863-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003863-31.